Partnering
How we collaborate with partners
We welcome partnerships that align with our strategy and deliver mutual value. By working with leading companies worldwide, we aim to amplify the clinical and societal impact of our product candidates.
Our preferred model is to engage early - co-creating solutions around high-value antimicrobial targets. By applying our platform broadly, we can develop new CRISPR-based approaches, from CRISPR-enabled bacteriophages to engineered live bacterial therapeutics with well-defined product profiles, helping partners achieve their objectives.
“Partnerships sit at the heart of our strategy: they help us accelerate innovation and extend the reach of our technology”
Collaboration with the Cystic Fibrosis Foundation
SNIPR is developing phage therapy intended to clear persistent Pseudomonas aeruginosa infections. These infections are common in people with cystic fibrosis (CF), can be multidrug-resistant, and often require prolonged courses of inhaled antibiotics. Because thick mucus accumulates in the lungs, people with CF are especially susceptible to bacterial infections that worsen disease over time.
Identifying optimal phages
To build an effective phage cocktail, we source naturally occurring bacteriophages - from individuals with CF and other lung conditions - and screen them under conditions that mirror the CF lung environment. Using our engineering platform, SNIPR will enhance selected phages to improve their ability to target and eliminate P. aeruginosa.
Support from the Cystic Fibrosis Foundation will accelerate the discovery and optimisation of engineered phages for P. aeruginosa infections and advance the most promising candidates into clinical development.
“Engineered phages seek to build upon successes already observed with naturally derived phages and may be the next evolution in understanding the full potential for phage therapy in cystic fibrosis or similar airway diseases”
Our Microbial Gene Therapy Pipeline
A common vision
We are committed to exploiting the full potential of our technology by working with partners to discover and develop new therapies based on our novel CRISPR-based modality. We are seeking companies interested in leveraging the power of our transformational science through R&D partnerships and creating novel therapies together.
We are particularly interested in partnering on the assets listed in the table above, including SNIPR004-IBD, SNIPR004-T2D and SNIPR-DOPA. For these programs, we welcome strategic collaborations spanning co-development, out-licensing, or indication expansion to fully realize their therapeutic potential for patients.
SNIPR is committed to enabling and fueling the development of innovative therapies using the technologies covered by its patent estate. To this end, SNIPR is making its technologies available to third parties for research purposes. For non-commercial academic and non-profit use, no written license to SNIPR’s CRISPR tools, methods, or other intellectual property is necessary.
Talk to us:
partnering@sniprbiome.com